{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:19:40Z","timestamp":1793323180512,"version":"4.5.0"},"reference-count":86,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ EBM"],"accepted":{"date-parts":[[2025,8,16]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of our study was to assess the benefits and harms of tramadol vs placebo in adults with chronic pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>The research method was a systematic review of randomised clinical trials with meta-analysis. The review followed the Trial Sequential Analysis and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>The Cochrane Library, MEDLINE, Embase, Science Citation Index and BIOSIS were searched for trials published from inception to 6 February 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                    <jats:p>Studies were eligible for inclusion if they were published and unpublished randomised clinical trials comparing tramadol vs placebo in adults with any type of chronic pain. Risk of bias was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The main outcome measures were pain level, adverse events, quality of life, dependence, abuse and depressive symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 19 randomised placebo-controlled clinical trials enrolling 6506 participants. All outcome results were at high risk of bias. Meta-analysis and Trial Sequential Analysis showed evidence of a beneficial effect of tramadol on chronic pain (mean difference numerical rating scale (NRS) \u22120.93 points; 97.5%\u2009CI \u22121.26 to \u22120.60; p&lt;0.0001; low certainty of evidence). However, the effect size was below our predefined minimal important difference of 1.0 point on NRS. Beta binomial regression showed evidence of a harmful effect of tramadol on serious adverse events (OR 2.13; 97.5%\u2009CI 1.29 to 3.51; p=0.001; moderate certainty of evidence), mainly driven by a higher proportion of cardiac events and neoplasms. It was not possible to conduct a meta-analysis of the quality of life due to a lack of data. Meta-analysis and Trial Sequential Analysis showed that tramadol increased the risk of several non-serious adverse events including nausea (number needed to harm (NNH) 7), dizziness (NNH 8), constipation (NNH 9), and somnolence (NNH 13) (all very low certainty of evidence).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tramadol may have a slight effect on reducing chronic pain levels (low certainty of evidence) while likely increasing the risk of both serious (moderate certainty of evidence) and non-serious adverse events (very low certainty of evidence). The potential harms associated with tramadol use for pain management likely outweigh its limited benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjebm-2025-114101","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:16Z","timestamp":1759881616000},"page":"160-169","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Tramadol versus placebo for chronic pain: a systematic review with meta-analysis and trial sequential analysis"],"prefix":"10.1136","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-6719","authenticated-orcid":false,"given":"Jehad Ahmad","family":"Barakji","sequence":"first","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen, The Capital Region, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-7295","authenticated-orcid":false,"given":"Mathias","family":"Maagaard","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen, The Capital Region, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne Juul","family":"Petersen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen, The Capital Region, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef Ahmad","family":"Barakji","sequence":"additional","affiliation":[{"name":"Department of Radiology, Copenhagen University Hospital - North Zealand Hospital, Hiller\u00f8d Hospital, Hiller\u00f8d, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6166-923X","authenticated-orcid":false,"given":"Emil \u00d8rskov","family":"Ipsen","sequence":"additional","affiliation":[{"name":"Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital Koge, K\u00f8ge, Region Zealand, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen, The Capital Region, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Mathiesen","sequence":"additional","affiliation":[{"name":"Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital Koge, K\u00f8ge, Region Zealand, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen, The Capital Region, Denmark"},{"name":"Department of Regional Health Research, University of Southern Denmark Faculty of Health Sciences, Odense, Region Syddanmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2026052102101711000_31.3.160.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(98)00117-1"},{"key":"2026052102101711000_31.3.160.2","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.140"},{"key":"2026052102101711000_31.3.160.3","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(86)90224-1"},{"key":"2026052102101711000_31.3.160.4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000184"},{"key":"2026052102101711000_31.3.160.5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl380"},{"key":"2026052102101711000_31.3.160.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.08.008"},{"key":"2026052102101711000_31.3.160.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ackd.2005.03.008"},{"key":"2026052102101711000_31.3.160.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00907-7"},{"key":"2026052102101711000_31.3.160.9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03370708"},{"key":"2026052102101711000_31.3.160.10","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg105"},{"key":"2026052102101711000_31.3.160.11","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005020157"},{"key":"2026052102101711000_31.3.160.12","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2013.13750","article-title":"Frequency and severity of pain and symptom distress among patients with chronic kidney disease receiving dialysis","volume":"143","author":"Gamondi","year":"2013","journal-title":"Swiss Med Wkly"},{"key":"2026052102101711000_31.3.160.13","article-title":"Tramadol for neuropathic pain in adults","volume":"6","author":"Duehmke","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052102101711000_31.3.160.14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/08897077.2012.735216","article-title":"Topical review on the abuse and misuse potential of tramadol and tilidine in Germany","volume":"34","author":"Radbruch","year":"2013","journal-title":"Subst Abus"},{"key":"2026052102101711000_31.3.160.15","first-page":"717","article-title":"The role of tramadol in current treatment strategies for musculoskeletal pain","volume":"3","author":"Schug","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"2026052102101711000_31.3.160.16","unstructured":"Tramadol . World drug report. Geneva United Nations Office on Drugs and Crime; 2014. Available: https:\/\/www.unodc.org\/documents\/wdr2014\/World_Drug_Report_2014_web.pdf"},{"key":"2026052102101711000_31.3.160.17","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31815b035b"},{"key":"2026052102101711000_31.3.160.18","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00004"},{"key":"2026052102101711000_31.3.160.19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200666020-00006","article-title":"Tramadol Sustained-Release Capsules","volume":"66","author":"Keating","year":"2006","journal-title":"Drugs"},{"key":"2026052102101711000_31.3.160.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0720-4"},{"key":"2026052102101711000_31.3.160.21","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060010-00008"},{"key":"2026052102101711000_31.3.160.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2020.01.361"},{"key":"2026052102101711000_31.3.160.23","unstructured":"Cancer pain relief: with a guide to opioid availability. World Health Organization, 1996. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/37896\/9241544821.pdf?sequence=1&isAllowed=y"},{"key":"2026052102101711000_31.3.160.24","doi-asserted-by":"crossref","first-page":"ES9","DOI":"10.36076\/ppj.2012\/15\/ES9","article-title":"Opioid Epidemic in the United States","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Phys"},{"key":"2026052102101711000_31.3.160.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k2833","article-title":"Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study","volume":"362","author":"Jeffery","year":"2018","journal-title":"BMJ"},{"key":"2026052102101711000_31.3.160.26","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00704","article-title":"A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans","volume":"10","author":"Dunn","year":"2019","journal-title":"Front Psychiatry"},{"key":"2026052102101711000_31.3.160.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l1849","article-title":"Chronic use of tramadol after acute pain episode: cohort study","volume":"365","author":"Thiels","year":"2019","journal-title":"BMJ"},{"key":"2026052102101711000_31.3.160.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18472"},{"key":"2026052102101711000_31.3.160.29","article-title":"Tramadol for osteoarthritis","volume":"5","author":"Toupin April","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052102101711000_31.3.160.30","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-023-02307-0","article-title":"Tramadol for chronic pain in adults: protocol for a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials","volume":"12","author":"Barakji","year":"2023","journal-title":"Syst Rev"},{"key":"2026052102101711000_31.3.160.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2026052102101711000_31.3.160.32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2026052102101711000_31.3.160.33","first-page":"231","article-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use","volume":"48","year":"1997","journal-title":"Int Dig Health Legis"},{"key":"2026052102101711000_31.3.160.34","doi-asserted-by":"crossref","unstructured":"Higgins J , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions: cochrane handbook. 2019. Available: https:\/\/training.cochrane.org\/handbook\/current","DOI":"10.1002\/9781119536604"},{"key":"2026052102101711000_31.3.160.35","unstructured":"StataCorp . Stata: release 14 [program]. College Station, TX: StataCorp LP; 2014. Available: https:\/\/www.stata.com\/company\/"},{"key":"2026052102101711000_31.3.160.36","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026052102101711000_31.3.160.37","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780060325"},{"key":"2026052102101711000_31.3.160.38","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026052102101711000_31.3.160.39","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001320"},{"key":"2026052102101711000_31.3.160.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-022-01763-x","article-title":"Rescaling pain intensity measures for meta-analyses of analgesic medicines for low back pain appears justified: an empirical examination from randomised trials","volume":"22","author":"Wewege","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"2026052102101711000_31.3.160.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2026052102101711000_31.3.160.42","unstructured":"GRADEpro GDT: GRADEpro guideline development tool [software]. McMaster University and Evidence Prime; 2022. Available: https:\/\/www.gradepro.org\/"},{"key":"2026052102101711000_31.3.160.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2022.07.014"},{"key":"2026052102101711000_31.3.160.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2018.05.007"},{"key":"2026052102101711000_31.3.160.45","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079971","article-title":"Common interventional procedures for chronic non-cancer spine pain: a systematic review and network meta-analysis of randomised trials","volume":"388","author":"Wang","year":"2025","journal-title":"BMJ"},{"key":"2026052102101711000_31.3.160.46","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2380"},{"key":"2026052102101711000_31.3.160.47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2026052102101711000_31.3.160.48","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200727010-00007"},{"key":"2026052102101711000_31.3.160.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(03)00020-4"},{"key":"2026052102101711000_31.3.160.50","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1842"},{"key":"2026052102101711000_31.3.160.51","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/papr.13190","article-title":"Efficacy and safety of twice-daily tramadol hydrochloride bilayer sustained-release tablets with an immediate release component for postherpetic neuralgia: Results of a Phase III, randomized, double-blind, placebo-controlled, treatment-withdrawal study","volume":"23","author":"Kawai","year":"2023","journal-title":"Pain Pract"},{"key":"2026052102101711000_31.3.160.52","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31818a744d"},{"key":"2026052102101711000_31.3.160.53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15360288.2024.2384968","article-title":"Topical Formulation of Tramadol 5% in the Management of Osteoarthritis of the Knee: A Double-Blind, Randomized, Prospective, Placebo-Controlled Clinical Trial","volume":"39","author":"Ala","year":"2025","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2026052102101711000_31.3.160.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2003.11.006"},{"key":"2026052102101711000_31.3.160.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2006.11.017"},{"key":"2026052102101711000_31.3.160.56","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181cec307"},{"key":"2026052102101711000_31.3.160.57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0011-393X(01)80021-7","article-title":"Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Fleischmann","year":"2001","journal-title":"Curr Ther Res"},{"key":"2026052102101711000_31.3.160.58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5055\/jom.2007.0015","article-title":"Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid\u00ae OAD)","volume":"3","author":"Fishman, MD","year":"2007","journal-title":"J Opioid Manag"},{"key":"2026052102101711000_31.3.160.59","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X115595"},{"key":"2026052102101711000_31.3.160.60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40261-022-01139-5","article-title":"Efficacy and Safety of Tramadol Hydrochloride Twice-Daily Sustained-Release Bilayer Tablets with an Immediate-Release Component for Chronic Pain Associated with Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study","volume":"42","author":"Kawai","year":"2022","journal-title":"Clin Drug Investig"},{"key":"2026052102101711000_31.3.160.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.005"},{"key":"2026052102101711000_31.3.160.62","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40122-022-00424-7","article-title":"Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial","volume":"11","author":"Markman","year":"2022","journal-title":"Pain Ther"},{"key":"2026052102101711000_31.3.160.63","first-page":"772","article-title":"Efficacy of tramadol in treatment of chronic low back pain","volume":"27","author":"Schnitzer","year":"2000","journal-title":"J Rheumatol"},{"key":"2026052102101711000_31.3.160.64","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.726216"},{"key":"2026052102101711000_31.3.160.65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5055\/jom.2008.0013","article-title":"Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain","volume":"4","author":"Vorsanger","year":"2008","journal-title":"J Opioid Manag"},{"key":"2026052102101711000_31.3.160.66","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-200010000-00003"},{"key":"2026052102101711000_31.3.160.67","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X199493"},{"key":"2026052102101711000_31.3.160.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.12.085"},{"key":"2026052102101711000_31.3.160.69","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.13005\/bpj\/3010","article-title":"Critical Assessment of Effectiveness and Safety of Tramadol and Evaluation of its Market in Ukraine","volume":"17","author":"Oleshchuk","year":"2024","journal-title":"Biomed Pharmacol J"},{"key":"2026052102101711000_31.3.160.70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197402282900907"},{"key":"2026052102101711000_31.3.160.71","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39500.677199.AE"},{"key":"2026052102101711000_31.3.160.72","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026052102101711000_31.3.160.73","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"2026052102101711000_31.3.160.74","article-title":"Tramadol with or without paracetamol (acetaminophen) for cancer pain","volume":"5","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052102101711000_31.3.160.75","doi-asserted-by":"publisher","DOI":"10.3310\/hta16150"},{"key":"2026052102101711000_31.3.160.76","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520290060030"},{"key":"2026052102101711000_31.3.160.77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04149-5"},{"key":"2026052102101711000_31.3.160.78","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-11-200112040-00010"},{"key":"2026052102101711000_31.3.160.79","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-149-3-200808050-00023","article-title":"Correction: reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"149","author":"Gluud","year":"2008","journal-title":"Ann Intern Med"},{"key":"2026052102101711000_31.3.160.80","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39465.451748.AD"},{"key":"2026052102101711000_31.3.160.81","article-title":"Industry sponsorship and research outcome","volume":"12","author":"Lundh","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026052102101711000_31.3.160.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2003.08.001"},{"key":"2026052102101711000_31.3.160.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.09.002"},{"key":"2026052102101711000_31.3.160.84","article-title":"Opioid crisis: addiction, overprescription, and insufficient primary prevention","volume":"23","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2026052102101711000_31.3.160.85","unstructured":"Opioid overdose. World Health Organization; 2023. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/opioid-overdose"},{"key":"2026052102101711000_31.3.160.86","unstructured":"Drug overdose deaths: facts and figures. National Institute on Drug Abuse; 2024. Available: https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"}],"container-title":["BMJ Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjebm-2025-114101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:11:55Z","timestamp":1779354715000},"score":1,"resource":{"primary":{"URL":"https:\/\/ebm.bmj.com\/lookup\/doi\/10.1136\/bmjebm-2025-114101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":86,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjebm-2025-114101"],"URL":"https:\/\/doi.org\/10.1136\/bmjebm-2025-114101","relation":{},"ISSN":["2515-446X","2515-4478"],"issn-type":[{"value":"2515-446X","type":"print"},{"value":"2515-4478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}